Page 59 - AN-2-2

Advanced Neurology Seizures and CKD

145. Almeida L, Soares-da-Silva P, 2007, Eslicarbazepine acetate 156. Rosenfeld WE, 1997, Topiramate: A review of preclinical,
(BIA 2-093). Neurotherapeutics, 4: 88–96. pharmacokinetic, and clinical data. Clin Ther, 19: 1294–1308.
https://doi.org/10.1016/j.nurt.2006.10.005 https://doi.org/10.1016/s0149-2918(97)80006-9
146. Kandrotas RJ, Love JM, Gal P, et al., 1990, The effect of 157. Lamb EJ, Stevens PE, Nashef L, 2004, Topiramate increases
hemodialysis and hemoperfusion on serum valproic acid biochemical risk of nephrolithiasis. Ann Clin Biochem,
concentration. Neurology, 40: 1456. 41: 166–169.
https://doi.org/10.1212/wnl.40.9.1456 https://doi.org/10.1258/000456304322880104
147. Gillard M, Chatelain P, Fuks B, 2006, Binding characteristics 158. Leppik IE, 2004, Zonisamide: Chemistry, mechanism of
of levetiracetam to synaptic vesicle protein 2A (SV2A) action, and pharmacokinetics. Seizure, 13: S5-S9.
in human brain and in CHO cells expressing the human https://doi.org/10.1016/j.seizure.2004.04.016
recombinant protein. Eur J Pharmacol, 536: 102–108.
159. Ijiri Y, Inoue T, Fukuda F, et al., 2004, of the antiepileptic
https://doi.org/10.1016/j.ejphar.2006.02.022 drug zonisamide in patients undergoing hemodialysis.
148. Lynch BA, Lambeng N, Nocka K, et al., 2004, The synaptic Epilepsia, 45: 924–927.
vesicle protein SV2A is the binding site for the antiepileptic https://doi.org/10.1111/j.0013-9580.2004.30603.x
drug levetiracetam. Proc Natl Acad Sci, 101: 9861–9866.
160. Rogawski MA, Tofighy A, White HS, et al., 2015, Current
https://doi.org/10.1073/pnas.0308208101 understanding of the mechanism of action of the
149. Chang WP, Südhof TC, 2009, SV2 renders primed synaptic antiepileptic drug lacosamide. Epilepsy Res, 110: 189–205.
vesicles competent for Ca2+-induced exocytosis. J Neurosci, https://doi.org/10.1016/j.eplepsyres.2014.11.021
29: 883–897.
161. Jo S, Bean BP, 2017, Lacosamide inhibition of Nav1. 7
https://doi.org/10.1523/JNEUROSCI.4521-08.2009 voltage-gated sodium channels: Slow binding to fast-
150. Deshpande LS, DeLorenzo RJ, 2014, Mechanisms of inactivated states. Mol Pharmacol, 91: 277–286.
levetiracetam in the control of status epilepticus and https://doi.org/10.1124/mol.116.106401
epilepsy. Front Neurol, 5: 11.
162. Cawello W, Fuhr U, Hering U, et al., 2013, Impact of impaired
https://doi.org/10.3389/fneur.2014.00011 renal function on the pharmacokinetics of the antiepileptic
drug lacosamide. Clin Pharmacokinet, 52: 897–906.
151. Carunchio I, Pieri M, Ciotti MT, et al., 2007, Modulation of
AMPA receptors in cultured cortical neurons induced by the https://doi.org/10.1007/s40262-013-0080-7
antiepileptic drug levetiracetam. Epilepsia, 48: 654–662. 163. Goa KL, Ross SR, Chrisp P, 1993, Lamotrigine. Drugs,
https://doi.org/10.1111/j.1528-1167.2006.00973.x 46: 152–176.
152. Zona C, Pieri M, Carunchio I, et al., 2010, Brivaracetam https://doi.org/10.2165/00003495-199346010-00009
(ucb 34714) inhibits Na+current in rat cortical neurons in 164. Wootton R, Soul‐Lawton J, Rolan PE, et al., 1997,
culture. Epilepsy Res, 88: 46–54. Comparison of the pharmacokinetics of lamotrigine in
https://doi.org/10.1016/j.eplepsyres.2009.09.024 patients with chronic renal failure and healthy volunteers.
Br J Pharmacol, 43: 23–27.
153. Klitgaard H, Matagne A, Nicolas JM, et al., 2016,
Brivaracetam: Rationale for discovery and preclinical profile https://doi.org/10.1111/j.1365-2125.1997.tb00028.x
of a selective SV 2A ligand for epilepsy treatment. Epilepsia, 165. Smetana KS, Cook AM, Bastin ML, et al., 2016, Antiepileptic
57: 538–548. dosing for critically ill adult patients receiving renal
https://doi.org/10.1111/epi.13340 replacement therapy. J Crit Care, 36: 116–124.
154. Nicolas JM, Hannestad J, Holden D, et al., 2016, Brivaracetam, https://doi.org/10.1016/j.jcrc.2016.06.023
a selective high‐affinity synaptic vesicle protein 2A (SV 2A) 166. Perucca P, Dopp JM, editors. 2015, Gabapentin and
ligand with preclinical evidence of high brain permeability pregabalin. In: Wyllie’s Treatment of Epilepsy: Principles
and fast onset of action. Epilepsia, 57: 201–209. and Practice. Philadelphia, PA: Lippincott Williams and
https://doi.org/10.1111/epi.13267 Wilkins. p647–657.
155. Rolan P, Sargentini‐Maier ML, Pigeolet E, et al., 2008, The 167. Ochs HR, Greenblatt DJ, Kaschell HJ, et al., 1981,
pharmacokinetics, CNS pharmacodynamics and adverse Diazepam kinetics in patients with renal insufficiency or
event profile of brivaracetam after multiple increasing oral hyperthyroidism. Br J Pharmacol, 12: 829–832.
doses in healthy men. Br J Clin Pharmacol, 66: 71–75. https://doi.org/10.1111/j.1365-2125.1981.tb01315.x
https://doi.org/10.1111/j.1365-2125.2008.03158.x 168. Sankar R, 2012, GABAA receptor physiology and

https://doi.org/10.36922/an.314
33
Volume 2 Issue 2 (2023) olume 2 Issue 2 (2023)
V 33 https://doi.org/10.36922/an.314